Compare Stocks: ROIV, REGN, ARGX, and MRNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$1,002.31 -0.5%	$930.46	$661.85 ▼ $1,072.75	$62.70B	0.47	340,826 shs	209,896 shs
MRNA Moderna	$135.61 -3.4%	$88.67	$22.28 ▼ $176.66	$54.14B	1.1	11.61 million shs	8.58 million shs
REGN Regeneron Pharmaceuticals	$807.65 -0.3%	$745.94	$541.00 ▼ $859.34	$83.15B	0.2	833,428 shs	563,377 shs
ROIV Roivant Sciences	$41.81 +0.8%	$35.43	$13.40 ▼ $42.50	$30.20B	1.12	6.25 million shs	10.76 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-2.52%	-2.08%	+16.42%	+16.81%	+31.13%
MRNA Moderna	-3.59%	-9.04%	+137.16%	+205.13%	+465.16%
REGN Regeneron Pharmaceuticals	-2.10%	-1.64%	+3.31%	+34.68%	+45.10%
ROIV Roivant Sciences	+18.75%	+20.16%	+14.14%	+46.00%	+221.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$1,002.31 -0.5%	$930.46	$661.85 ▼ $1,072.75	$62.70B	0.47	340,826 shs	209,896 shs
MRNA Moderna	$135.61 -3.4%	$88.67	$22.28 ▼ $176.66	$54.14B	1.1	11.61 million shs	8.58 million shs
REGN Regeneron Pharmaceuticals	$807.65 -0.3%	$745.94	$541.00 ▼ $859.34	$83.15B	0.2	833,428 shs	563,377 shs
ROIV Roivant Sciences	$41.81 +0.8%	$35.43	$13.40 ▼ $42.50	$30.20B	1.12	6.25 million shs	10.76 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-2.52%	-2.08%	+16.42%	+16.81%	+31.13%
MRNA Moderna	-3.59%	-9.04%	+137.16%	+205.13%	+465.16%
REGN Regeneron Pharmaceuticals	-2.10%	-1.64%	+3.31%	+34.68%	+45.10%
ROIV Roivant Sciences	+18.75%	+20.16%	+14.14%	+46.00%	+221.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.88	Moderate Buy	$1,158.61	15.59% Upside
MRNA Moderna	2.08	Hold	$76.72	-43.42% Downside
REGN Regeneron Pharmaceuticals	2.58	Moderate Buy	$800.36	-0.90% Downside
ROIV Roivant Sciences	2.85	Moderate Buy	$40.63	-2.83% Downside

Current Analyst Ratings Breakdown

Latest ROIV, REGN, ARGX, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $46.00
9/9/2026	ROIV Roivant Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
9/9/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
9/8/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$41.00 ➝ $47.00
9/8/2026	ROIV Roivant Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$42.00 ➝ $52.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
9/3/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,150.00
9/3/2026	MRNA Moderna	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$40.00 ➝ $81.00
8/31/2026	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,230.00 ➝ $1,250.00
8/28/2026	MRNA Moderna	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	14.76	$20.70 per share	48.43	$118.34 per share	8.47
MRNA Moderna	$2.21B	24.50	N/A	N/A	$22.14 per share	6.13
REGN Regeneron Pharmaceuticals	$15.53B	5.35	$40.96 per share	19.72	$295.66 per share	2.73
ROIV Roivant Sciences	$7.53M	4,009.60	N/A	N/A	$7.35 per share	5.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	38.49	26.89	1.07	32.19%	43.59%	36.66%	N/A
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	19.96	15.98	1.62	27.86%	13.47%	10.34%	10/28/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)

Latest ROIV, REGN, ARGX, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.47%	N/A	9.29%	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Latest ROIV, REGN, ARGX, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
MRNA Moderna	0.09	2.29	2.18
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
ROIV Roivant Sciences	N/A	16.72	16.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
MRNA Moderna	75.33%
REGN Regeneron Pharmaceuticals	83.31%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
MRNA Moderna	10.80%
REGN Regeneron Pharmaceuticals	6.97%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
ROIV Roivant Sciences	860	722.32 million	658.76 million	Optionable

ROIV, REGN, ARGX, and MRNA Headlines

Recent News About These Companies

Roivant Reports 56.3% Placebo-Adjusted PVR Reduction In Phase 2 Mosliciguat PH-ILD Study, Starts Phase 3 PHrontier Trial

3 hours ago | pulse2.comP

Roivant Sciences' Pulmovant Reports Positive Phase 2 Results for Mosliciguat in PH-ILD

September 9 at 8:26 AM | marketscreener.comM

These 2 biotech stocks hit record highs today – what’s driving the rallies?

September 9 at 3:26 AM | msn.com

Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%

September 8 at 11:30 PM | insidermonkey.com

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

September 8 at 10:25 PM | marketwatch.com

Roivant Sciences soars 19% on positive mosliciguat trial results

September 8 at 10:25 PM | seekingalpha.com

Roivant Sciences stock soars as lung disease drug hits goals

September 8 at 10:25 PM | msn.com

Roivant (ROIV) Soars to All-Time High; Q2 Hedge Fund Holdings Surge 41%

September 8 at 10:25 PM | finance.yahoo.com

Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 8 at 5:00 PM | seekingalpha.com

HC Wainwright Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock Price

September 8 at 1:53 PM | marketbeat.com

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript

September 8 at 1:00 PM | seekingalpha.com

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils ...

September 8 at 12:23 PM | markets.businessinsider.com

Roivant's experimental lung disease drug meets goals in mid-stage study

September 8 at 12:23 PM | msn.com

Why these two hot biotech stocks just surged to record highs

September 8 at 12:23 PM | msn.com

Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results

September 8 at 12:23 PM | finance.yahoo.com

Roivant Sciences Sees Unusually High Options Volume (NASDAQ:ROIV)

September 8 at 12:19 PM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

September 8 at 12:05 PM | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High - Should You Buy?

September 8 at 9:39 AM | marketbeat.com

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

September 8 at 6:00 AM | globenewswire.com

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

September 8 at 6:00 AM | globenewswire.com

Roivant Wins Approval for the First Oral Dermatomyositis Drug. How Large is the Opportunity?

September 7 at 8:51 PM | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ROIV, REGN, ARGX, and MRNA Company Descriptions

argenex NASDAQ:ARGX

$1,002.31 -4.76 (-0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$1,002.98 +0.67 (+0.07%)

As of 04:15 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Moderna NASDAQ:MRNA

$135.61 -4.72 (-3.36%)

Closing price 04:00 PM Eastern

Extended Trading

$135.59 -0.02 (-0.01%)

As of 04:26 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$807.65 -2.66 (-0.33%)

Closing price 04:00 PM Eastern

Extended Trading

$807.62 -0.02 (0.00%)

As of 04:26 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Roivant Sciences NASDAQ:ROIV

$41.81 +0.33 (+0.80%)

Closing price 04:00 PM Eastern

Extended Trading

$42.00 +0.19 (+0.45%)

As of 04:26 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ROIV, REGN, ARGX, and MRNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ROIV, REGN, ARGX, and MRNA Earnings

Compare Dividends

Latest ROIV, REGN, ARGX, and MRNA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ROIV, REGN, ARGX, and MRNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ROIV, REGN, ARGX, and MRNA Company Descriptions

argenex NASDAQ:ARGX

Moderna NASDAQ:MRNA

Regeneron Pharmaceuticals NASDAQ:REGN

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools